A Glenmark Therapeutics lança o Pataday Twice Daily Relief genérico, visando o mercado de US $ 26,4 milhões. Glenmark Therapeutics launches generic Pataday Twice Daily Relief, targeting $26.4M market.

A Glenmark Therapeutics Inc., uma subsidiária norte-americana da Glenmark Pharmaceuticals, lançou o Olopatadine Hydrochloride Ophthalmic Solution 0.1% (OTC), uma versão genérica do Pataday Twice Daily Relief, visando um mercado com vendas anuais de US $ 26,4 milhões. Glenmark Therapeutics Inc., a US subsidiary of Glenmark Pharmaceuticals, launched Olopatadine Hydrochloride Ophthalmic Solution 0.1% (OTC), a generic version of Pataday Twice Daily Relief, targeting a market with $26.4M annual sales. Fabio Moreno, Diretor de Vendas e Marketing da OTC, expressou entusiasmo com o lançamento, enfatizando o compromisso da empresa em atender às necessidades do mercado e fornecer soluções de OTC de alta qualidade. Fabio Moreno, Head of OTC Sales & Marketing, expressed excitement about the launch, emphasizing the company's commitment to meeting market needs and providing high-quality OTC solutions.